arrow
J

Jan Rekowski

The Institute of Cancer Research
H指数:24
被引数:2,191

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to “B7-H3 as a Therapeutic Target in Advanced Prostate Cancer” [European Urology 83 (2023) 224–238

勘误:“B7-H3 作为晚期前列腺癌的治疗靶点” [欧洲泌尿外科杂志 83 (2023) 224–238]

2026-08-070
OAAI
An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer

一项开放标签、I期剂量探索研究,评估单药IMU-935(一种新型RORγ/RORγt反向激动剂)在进展性转移性去势抵抗性前列腺癌患者中的疗效。

2026-03-110
OAAI
Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer

循环肿瘤细胞中的染色体不稳定性与转移性去势抵抗性前列腺癌中的卡巴他赛耐药性

2025-12-220
OA
Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer

开发针对MCL1和BCLXL的致死性前列腺癌的治疗策略

2025-11-100
OAAI
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer

阐明靶向MCL1的分子分层单药及联合治疗策略,以治疗致命性前列腺癌

2025-10-080
OAAI
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial

德法替尼联合阿瓦替尼治疗实体瘤患者: 1期框架试验

2025-06-270
OAAI
BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity
2024-09-170
OAAI
RNASEH2B loss and PARP inhibition in advanced prostate cancer
2024-06-040
OAAI
Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2024-02-272
OAAI
Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer

一种新的BAG-1L-Specific抗体的开发和验证,以量化晚期前列腺癌中的BAG-1L蛋白表达

2023-11-011
OAAI
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance

提高早期剂量发现临床试验的报告质量和影响: CONSORT剂量发现扩展 (CONSORT-DEFINE) 指南

2023-10-209
OAAI
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance

提高早期剂量发现临床试验方案的质量和影响: 精神剂量发现扩展 (SPIRIT-DEFINE) 指南

2023-10-207
OA
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance

靶向髓系趋化逆转前列腺癌治疗耐药

Nature
IF48.5
2023-10-160
OAAI
Circulating tumor DNA (ctDNA) low pass whole genome sequencing (lpWGS) studies identify genomic alterations associating with taxane outcomes in prospective phase III taxane trials for metastatic castration resistant prostate cancer (mCRPC) sufferers
2023-10-010
OA
BCL2 expression is enriched in AR-independent advanced prostate cancer
2023-06-021
PRE